Literature DB >> 8370954

Prevalence of antibodies to Chlamydia pneumoniae TWAR in a group of German medical students.

H M Freidank1, D Brauer.   

Abstract

Prevalence of antibodies to Chlamydia pneumoniae TWAR in Germany has not been previously evaluated. Therefore a healthy adult population of 353 German medical students (mean age 24 years) was examined with a species-specific microimmunofluorescence test for IgG, IgM and IgA antibodies to C. pneumoniae and in parallel to Chlamydia trachomatis. Altogether, 229 persons had IgG antibodies to C. pneumoniae (64.9%), 136 had IgA antibodies (38.5%), while the serum of only one contained specific IgM. Prevalence rates were higher in males (69.4%) than in females (57.3%). The total prevalence for antibodies to C. trachomatis was 5.9%. The results indicate that C. pneumoniae infections are highly endemic in Germany, and that primary infection probably takes place in children or young adults. Prevalence of antibodies to C. pneumoniae in this group of healthy young adults was about 10-fold higher than that to C. trachomatis. This finding needs to be taken into account when genus-specific tests are used for studying Chlamydial antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370954     DOI: 10.1016/0163-4453(93)94013-2

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  9 in total

1.  Evaluation of a new commercial microimmunofluorescence test for detection of antibodies to Chlamydia pneumoniae, Chlamydia trachomatis, and Chlamydia psittaci.

Authors:  H M Freidank; H Vögele; K Eckert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

2.  Prevalence of antibodies to Chlamydia pneumoniae in Slovenia.

Authors:  D Kese; H Hren-Vencelj; M Socan; B Beovic; M Cizman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-06       Impact factor: 3.267

3.  Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile.

Authors:  L J Murray; D P O'Reilly; G M Ong; C O'Neill; A E Evans; K B Bamford
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

4.  Identification of Chlamydia pneumoniae-specific protein antigens in immunoblots.

Authors:  H M Freidank; A S Herr; E Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

5.  Prevalence of Chlamydia pneumoniae specific antibodies in different clinical situations and healthy subjects in Izmir, Turkey.

Authors:  M Gencay; D Dereli; E Ertem; D Serter; M Puolakkainen; P Saikku; B Boydak; S Dereli; B Ozbakkaloglu; A Yorgancioglu; E Tez
Journal:  Eur J Epidemiol       Date:  1998-07       Impact factor: 8.082

6.  Chlamydia pneumoniae and asthma.

Authors:  P J Cook; P Davies; W Tunnicliffe; J G Ayres; D Honeybourne; R Wise
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

7.  Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections.

Authors:  R P Verkooyen; D Willemse; S C Hiep-van Casteren; S A Joulandan; R J Snijder; J M van den Bosch; H P van Helden; M F Peeters; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

8.  Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of conventional Chlamydia pneumoniae serology.

Authors:  Kh Shamsur Rahman; Bernhard Kaltenboeck
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

9.  Presence of Chlamydophila pneumoniae DNA in blood cells is a frequent event in patients with the late stage of primary cutaneous lymphomas and with atopic dermatitis.

Authors:  Bogusław Nedoszytko; Piotr Wierzbicki; Leena Karenko; Agata Maciejewska-Radomska; Przemysław Stachewicz; Monika Zabłotna; Jolanta Gleń; Liisa Väkevä; Roman J Nowicki; Małgorzata Sokołowska-Wojdyło
Journal:  Postepy Dermatol Alergol       Date:  2018-06-18       Impact factor: 1.837

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.